Antihypertensive and organ-protective effects of benazepril

References

• Bicket DP. Using ACE inhibitors appropriately. Am. Fam. Physician66, 461–468 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet335, 765–774 (1990).
   PubMed Web of Science ®Google Scholar
• Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Roseic E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens.27, 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am. J. Hypertens.14, 241–247 (2001).
   PubMed Web of Science ®Google Scholar
• Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet353, 2008–2013 (1999).
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br. Med. J.326, 1427 (2003).
   PubMed Web of Science ®Google Scholar
• Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam. Clin. Pharmacol.24, 3–8 (2010).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Divisón JA, Medialdea F. Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population. Expert Rev. Cardiovasc. Ther.6, 1063–1069 (2008).
   PubMedGoogle Scholar
• Rosenthal T, Gavras I. Fixed-drug combinations as first-line treatment for hypertension. Prog. Cardiovasc. Dis.48, 416–425 (2006).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Echarri R. Fixed combinations in the management of hypertension: perspective on lercanidipine–enalapril. Vasc. Health Risk Manag.4, 847–853 (2008).
   PubMedGoogle Scholar
• Barrios V. Combined therapy: the future has already come. Fundam. Clin. Pharmacol.24, 2 (2010).
   PubMed Web of Science ®Google Scholar
• Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med.122, 290–300 (2009).
   PubMed Web of Science ®Google Scholar
• Destro M, Cagnoni F, D’Ospina A et al. Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update. Vasc. Health Risk Manag.6, 253–260 (2010).
   PubMedGoogle Scholar
• Schmeider RE. The role of fixed-dose combination therapy with drugs that target the renin–angiotensin system in the hypertension paradigm. Clin. Exp. Hypertens.32, 35–42 (2010).
   PubMed Web of Science ®Google Scholar
• Ma TK, Kam KK, Yan BP, Lam YY. Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status. Br. J. Pharmacol.160, 1273–1292 (2010).
   PubMed Web of Science ®Google Scholar
• Campbell NR, Khan NA, Hill MD et al. 2009 Canadian Hypertension Education Program recommendations: the scientific summary – an annual update. Can. J. Cardiol.25, 271–277 (2009).
   PubMedGoogle Scholar
• Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am. J. Health Syst. Pharm.64, 1279–1283 (2007).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med.120, 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension55, 399–407 (2010).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation119, 391–479 (2009).
   PubMed Web of Science ®Google Scholar
• Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J. Clin. Invest.65, 1257–1264 (1980).
   PubMed Web of Science ®Google Scholar
• Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J. Pharmacol. Exp. Ther.279, 703–712 (1996).
   PubMedGoogle Scholar
• Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med.339, 1285–1292 (1998).
   PubMed Web of Science ®Google Scholar
• Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J. Am. Coll. Cardiol.2, 755–763 (1983).
   PubMed Web of Science ®Google Scholar
• Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation70, 271–278 (1984).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Dargie HJ, Hodsman GP et al. Captopril in heart failure: a double blind controlled trial. Br. Heart J.52, 530–535 (1984).
   PubMedGoogle Scholar
• Cleland JG, Dargie HJ, Ball SG et al. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br. Heart J.54, 305–312 (1985).
   PubMedGoogle Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med.316, 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M, for the Fosinopril Efficacy/Safety Trial (FEST) Study Group. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur. Heart J.16, 1892–1899 (1995).
   PubMedGoogle Scholar
• Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin. J. Am. Soc. Nephrol.1, 8–18 (2006).
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil.14, 1–113 (2007).
   PubMed Web of Science ®Google Scholar
• Chronic Kidney Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet375, 2073–2081 (2010).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilevia AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med.351, 1941–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Brenner B, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345, 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis E, Hunsicker LG, Clarke WR, Berl T et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis E, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med.329, 1456–1462 (1993).
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Tettamanti F, Tettamanzi D, Lusardi P, Motolese M. Fixed combination of benazepril and very low dose hydrochlorothiazide in the treatment of mild to moderate essential hypertension: evaluation by 24-hour non invasive ambulatory blood pressure monitoring. Int. J. Clin. Pharmacol. Ther.32, 606–611 (1994).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P; GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int.73, 1303–1309 (2008).
   PubMed Web of Science ®Google Scholar
• Whalen JJ. Definition of the effective dose of the converting-enzyme inhibitor benazepril. Am. Heart J.117, 728–734 (1989).
   PubMed Web of Science ®Google Scholar
• Kaiser G. Benazepril – pharmacokinetic profile in specific subpopulations. In: Benazepril: Profile of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 29–39 (1990).
   Google Scholar
• Chen DS, Dotson RA, Burrell RD, Watkins BE. Two potent angiotensin-converting enzyme (ACE) inhibitors: CGS 14 824 A and CGS 14 831. Pharmacologist25, 240 (1983).
   Google Scholar
• Balfour JA, Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs42, 511–539 (1991).
   PubMed Web of Science ®Google Scholar
• Chen B, Perich R, Jackson B et al. Inhibition of tissue ACE by benazepril. In: Benazepril: Profile of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 17–27 (1990).
   Google Scholar
• Johnston CI, Cubela R, Jackson B. Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat. Clin. Exp. Pharmacol. Physiol.15, 123–129 (1988).
   PubMed Web of Science ®Google Scholar
• Johnston CI, Fabris B, Yamada H et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J. Hypertens.7, 11–16 (1989).
   Google Scholar
• Norman JA, Lehmann M, Goodman FR, Barclay BW, Zimmerman MB. Central and peripheral inhibition of angiotensin converting enzyme (ACE) in the SHR: correlation with the antihypertensive activity of ACE inhibitors. Clin. Exp. Hypertens. A9, 461–468 (1987).
   PubMed Web of Science ®Google Scholar
• Zimmerman MB, Barclay BW, Lehmann M, Norman JA. Effects of chronic administration of angiotensin converting enzyme (ACE) inhibitors on blood pressure and tissue ACE activity in the SHR. Clin. Exp. Hypertens. A9, 473–476 (1987).
   PubMed Web of Science ®Google Scholar
• Bidiville J, Porchet M, Bussien JP, Nussberger J, Waeber B, Brunner HR. Effect of eight-day converting enzyme inhibition on ambulatory blood pressure recordings in normotensive volunteers. Arch. Int. Pharmacodyn. Ther.288, 109–119 (1987).
   PubMedGoogle Scholar
• Juillerat L, Nussberger J, Ménard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension16, 564–572 (1990).
   PubMed Web of Science ®Google Scholar
• Schaller MD, Nussberger J, Waeber B et al. Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers. Eur. J. Clin. Pharmacol.28, 267–272 (1985).
   PubMed Web of Science ®Google Scholar
• Waeber G, Fasanella d’Amore T, Nussberger J, Waeber B, Brunner HR. Effect on blood pressure and the renin–angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A. Eur. J. Clin. Pharmacol.31, 643–646 (1987).
   PubMed Web of Science ®Google Scholar
• Insel J, Mirvis DM, Boland MJ et al. A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. Clin. Pharmacol. Ther.45, 312–320 (1989).
   PubMedGoogle Scholar
• Bedogna V, Valvo E, Casagrande P et al. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int.38, 101–107 (1990).
   PubMed Web of Science ®Google Scholar
• Ribner HS, Sagar KB, Glasser SP et al. Long-term therapy with benazepril in patients with congestive heart failure: effects on clinical status and exercise tolerance. J. Clin. Pharmacol.30, 1106–1111 (1990).
   PubMedGoogle Scholar
• Nussberger J, de Gasparo M, Juillerat L et al. Rapid measurement of total and active renin: plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A. Clin. Exp. Hypertens. A9, 1353–1366 (1987).
   PubMed Web of Science ®Google Scholar
• Nussberger J, Juillerat L, Perret F et al. Need for plasma angiotensin measurements to investigate converting-enzyme inhibition in humans. Am. Heart J.117, 717–722 (1989).
   PubMed Web of Science ®Google Scholar
• Agabiti-Rosei E, Rizzoni D, Zulli R et al. Sustained antihypertensive effects of benazepril demonstrated by ambulatory monitoring: placebo-controlled trial at two dosage levels. In: Benazepril: Profile of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 59–66 (1990).
   Google Scholar
• Oldenbroek C. Invasive 24-hour blood pressure monitoring in controlled trial of benazepril. In: Benazepril: Profile of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 67–75 (1990).
   Google Scholar
• Pessina AC, Mormino P, Palatnini P et al. Morning or evening benazepril administration in hypertension? A randomized study using intra-arterial blood pressure monitoring. In: Benazepril: Profile of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 59–65 (1990).
   Google Scholar
• Weinberger MH, Black HR, Lasseter KC et al. Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril hydrochloride. Clin. Pharmacol. Ther.47, 608–617 (1990).
   PubMedGoogle Scholar
• Rousseau MF, Gurné O, van Eyll C, Benedict CR, Pouleur H. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohumoral status in patients with ischemic heart disease. Circulation81, 123–129 (1990).
   Google Scholar
• Noormohamed FH, Fuller GN, Lant AF. Effect of salt balance on the renal and hemodynamic actions of benazepril in normal men. J. Clin. Pharmacol.29, 928–937 (1989).
   PubMedGoogle Scholar
• Valvo E, Casagrande P, Bedogna V et al. Systemic and renal effects of a new angiotensin converting enzyme inhibitor, benazepril, in essential hypertension. J. Hypertens.8, 991–995 (1990).
   PubMedGoogle Scholar
• Reams GP, Lau A, Bauer JH. Effect of benazepril monotherapy in subjects with hypertension associated with renal dysfunction. J. Clin. Pharmacol.29, 609–614 (1989).
   PubMedGoogle Scholar
• Kaiser G, Ackermann R, Brechbühler S, Dieterle W. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril. HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. Biopharm. Drug Dispos.10, 365–376 (1989).
   PubMed Web of Science ®Google Scholar
• Waldmeier F, Schmid K. Disposition of [14C]-benazepril hydrochloride in rat, dog and baboon. Absorption, distribution, kinetics, biotransformation and excretion. Arzneimittelforschung39, 62–67 (1989).
   PubMed Web of Science ®Google Scholar
• Kaiser G, Ackermann R, Gschwind HP et al. The influence of hepatic cirrhosis on the pharmacokinetics of benazepril hydrochloride. Biopharm. Drug Dispos.11, 753–764 (1990).
   PubMed Web of Science ®Google Scholar
• Waldmeier F, Kaiser G, Ackermann R et al. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. Xenobiotica21, 251–261 (1991).
   PubMed Web of Science ®Google Scholar
• Kaiser G, Ackermann R, Dieterle W et al. Pharmacokinetics and pharmacodynamics of the ace inhibitor benazepril hydrochloride in the elderly. Eur. J. Clin. Pharmacol.38, 379–385 (1990).
   PubMed Web of Science ®Google Scholar
• Gengo FM, Brady E. The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin. Cardiol.14, 44–55 (1991).
   Google Scholar
• MacDonald NJ, Elliott HL, Howie CA, Reid JL. Age and the pharmacodynamics and pharmacokinetics of benazepril. Br. J. Clin. Pharmacol.27, 707–708 (1989).
   Google Scholar
• MacNab M, Mallows S. Safety profile of benazepril in essential hypertension. Clin. Cardiol.14, 33–37 (1991).
   PubMedGoogle Scholar
• Ohnishi A, Tsuboi Y, Ishizaki T et al. Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin. Pharmacol. Ther.45, 657–665 (1989).
   PubMed Web of Science ®Google Scholar
• Kaiser G, Ackermann R, Sioufi A. Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am. Heart J.117, 746–751 (1989).
   PubMed Web of Science ®Google Scholar
• Guyene TT, Bellet M, Sassano P, Serrurier D, Corvol P, Ménard J. Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension. J. Hypertens.7, 1005–1012 (1989).
   PubMed Web of Science ®Google Scholar
• Hayes PC, Plevris JN, Bouchier IA. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. J. Hum. Hypertens.3, 153–158 (1989).
   PubMed Web of Science ®Google Scholar
• DeQuattro V. Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide. Clin. Cardiol.14, 28–55 (1991).
   Google Scholar
• Smith WM, Gomez HJ. The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol.14, 79–90 (1991).
   PubMedGoogle Scholar
• Bellet M, Whalen JJ, Bodin F, Serrurier D, Tanner K, Ménard J. Use of crossover trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril. J. Hypertens.8, 43–48 (1990).
   Google Scholar
• Francillon A, Heintzmann F, Serrurier D. Efficacy of benazepril as replacement therapy after failure of a first antihypertensive treatment. Therapie49, 95–99 (1994).
   PubMedGoogle Scholar
• Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch. Fam. Med.5, 17–25 (1996).
   PubMedGoogle Scholar
• Holwerda K, Hoogma RP, Oldenbroek C, Huige RC, Wester A, Rijnierse JM. Efficacy and safety of benazepril plus hydrochlorothiazide versus benazepril alone in hypertensive patients unresponsive to benazepril monotherapy. Clin. Ther.16, 942–951 (1994).
   PubMedGoogle Scholar
• Haziza HM, Francillon A, Mottier D, Heintzmann F, Serrurier D. [Antihypertensive action and predictive factors of efficacy of benazepril in mild-to-moderate hypertension: clinical trial in general medical practice on 16,987 patients.] Ann. Cardiol. Angélol.47, 33–41 (1998).
   PubMed Web of Science ®Google Scholar
• Adalet K, Nalbantgil I, Kiliççioğlu B et al. Multicenter double blind comparative trial with benazepril versus captopril in the treatment of mild to moderate hypertension. Med. Bull. Istanbul28, 2 (1995).
   Google Scholar
• Fogari R, Zoppi A, Lusardi P, Mugellini A, Bertocchi F. Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodipine extended release in elderly patients with mild-to-moderate essential hypertension. Curr. Therap. Res.59, 246–256 (1998).
   Google Scholar
• Izzo JL Jr, Purkayastha D, Hall D, Hilkert RJ. Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. J. Hum. Hypertens.24, 403–409 (2010).
   PubMed Web of Science ®Google Scholar
• Ueng KC, Lin LC, Voon WC et al. An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in Chinese patients with mild to moderate hypertension. Blood Press. Suppl.1, 24–31 (2008).
   PubMedGoogle Scholar
• Jamerson K, Bakris GL, Dahlöf B et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press.16, 80–86 (2007).
   PubMed Web of Science ®Google Scholar
• Jamerson KA. The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH). J. Clin. Hypertens.5, 29–35 (2003).
   PubMedGoogle Scholar
• Bramlage P. Fixed-dose combinations of renin–angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin. Pharmacother.10, 1755–1767 (2009).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet375, 1173–1181 (2010).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359, 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Weber MA, Bakris GL, Jamerson K et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J. Am. Coll. Cardiol.56, 77–85 (2010).
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet336, 370–371 (1990).
   PubMedGoogle Scholar
• Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet362, 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med.358, 1887–1898 (2008).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Escobar C, Echarri R, Barrios V. Combined therapy in the treatment of hypertension: but which? J. Hypertens.27, 1331 (2009).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Colfer HT, Ribner HS, Gradman A, Hughes V, Kapoor A, Laidlaw JC. Effects of once-daily benazepril therapy on exercise tolerance and manifestations of chronic congestive heart failure. Am. J. Cardiol.70, 354–358 (1992).
   PubMedGoogle Scholar
• Nordrehaug JE, Omsjø IH, Vollset SE. A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure. J. Intern. Med.231, 589–594 (1992).
   PubMedGoogle Scholar
• Ye JF, Liu DS. Effects of benazepril combined with valsartan on congestive heart failure. Di Yi Jun Yi Da Xue Xue Bao25, 1441–1447 (2005).
   PubMedGoogle Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis.39, 1–266 (2002).
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med.334, 939–945 (1996).
   PubMed Web of Science ®Google Scholar
• The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet349, 1857–1863 (1997).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J. Am. Soc. Nephrol.9, 2096–2101 (1998).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med.160, 685–693 (2000).
   PubMed Web of Science ®Google Scholar
• Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med.354, 131–140 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang GH, Hou FF, Zhang X, Liu QF. Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/l? Zhonghua Nei Ke Za Zhi44, 592–596 (2005).
   PubMedGoogle Scholar
• Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol.12, 2832–2837 (2001).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int.53, 1209–1216 (1998).
   PubMed Web of Science ®Google Scholar
• Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am. J. Kidney. Dis.27, 489–495 (1996).
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Akashiba A, Kameda T et al. Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology12, 294–298 (2007).
   PubMed Web of Science ®Google Scholar
• Shoda J, Kanno Y, Suzuki H. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern. Med.45, 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• De Cesaris R, Ranieri G, Andriani A et al. Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. Clin. Pharmacol. Ther.60, 472–478 (1996).
   PubMed Web of Science ®Google Scholar
• Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA285, 2719–2728 (2001).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern. Med.163, 1555–1565 (2003).
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B. Low-dose dual blockade of the renin–angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis.43, 260–268 (2004).
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type I diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol.14, 992–999 (2003).
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Antihypertensive agents: are all of them equal? South. Med. J.101, 779–780 (2008).
   PubMedGoogle Scholar
• Wyndham CRC, Atrial fibrillation: the most common arrhythmia. Tex. Heart Inst. J.27, 257–267 (2000).
   PubMed Web of Science ®Google Scholar
• Zaman Ag, Kearney MT, Schecter C, Worthley SG, Nolan J. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am. Heart J.147, 823–827 (2004).
   PubMedGoogle Scholar
• Liu L, Qu XF, Yu Y, Bai B, Huang YL. Effect of benazepril on atrial cytoskeleton remodeling in the canine atrial fibrillation models. Zhonghua Yi Xue Za Zhi89, 2718–2721 (2009).
   PubMedGoogle Scholar
• Pethica BD. Safety and tolerability of benazepril in the treatment of hypertension – an overview. In: Benazepril: Profile of a New ACE Inhibitor. Brunner HR, Salvetti A, Sever PS (Eds). Royal Society of Medicine Services International Congress and Symposium Series 166. Royal Society of Medicine Services Limited, London, UK, 161–167 (1990).
   Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med.117, 234–242 (1992).
   PubMed Web of Science ®Google Scholar
• Amir M, Khan B, Tahir M. Incidence of angiotensin converting enzyme inhibitor induced cough. Prof. Med. J.12, 435–439 (2005).
   Google Scholar
• Lu J, Li LM, Cao WH, Zhan SY, Hu YH. Postmarketing surveillance on Benazepril. Zhonghua Liu Xing Bing Xue Za Zhi25, 412–416 (2004).
   PubMedGoogle Scholar
• Tomlinson B, Woo J, Thomas GN, Chau YM, Critchley JA. Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult chinese patients with hypertension. Clin. Ther.26, 1292–1304 (2004).
   PubMed Web of Science ®Google Scholar
• Slater EE, Merrill DD, Guess HA et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA260, 967–970 (1988).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358, 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Barrios V, Banegas JR, Ruilope LM, Rodicio JL. Evolution of blood pressure control in Spain. J. Hypertens.25, 1975–1977 (2007).
   PubMed Web of Science ®Google Scholar
• Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch. Intern. Med.167, 141–147 (2007).
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Perkovic V, de Galan et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol.27, 172–181 (2007).
   Google Scholar